Tissue and Cell Extraction and Purification
EP10011	Neuromics	100 Tests	EUR 444.6

All Competitors Laboratories manufactures the antibodyes reagents distributed by Genprice. The Antibodyes reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact All Competitors. Other Antibodyes products are available in stock. Specificity: Antibodyes Category:

True Blue Chloride
Toronto Research Chemicals	100mg	EUR 11200
Description: 71431-30-6

True north Cryobox1.5/2mLNatural
Scientific Laboratory Supplies	PK10	EUR 129.6

True Blue Diaceturate Salt
Toronto Research Chemicals	100mg	EUR 15000
Description: 108321-12-6

True Blue (TB) Diaceturate Salt
Polysciences Europe GmbH	1mg	Ask for price
Description: 108321-12-6

True Blue (TB) Diaceturate Salt
Polysciences Europe GmbH	5mg	Ask for price
Description: 108321-12-6

Dog True insulin ELISA kit
BlueGene	192 tests	EUR 1524
Description: A competitive ELISA for quantitative measurement of Canine True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Dog True insulin ELISA kit
BlueGene	1 plate of 48 wells	EUR 624
Description: A competitive ELISA for quantitative measurement of Canine True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Serum / Plasma information

VISTA Antibody [9E4]
MBS154606-01mg	MyBiosource	0.1mg	EUR 500

VISTA Antibody [9E4]
MBS154606-5x01mg	MyBiosource	5x0.1mg	EUR 2230

ARF1 antibody | E01/8D1
MBS226266-01mL	MyBiosource	0.1mL	EUR 485

ARF1 antibody | E01/8D1
MBS226266-5x01mL	MyBiosource	5x0.1mL	EUR 2015

ARNT antibody | E01/1H8
MBS226268-01mL	MyBiosource	0.1mL	EUR 485

ARNT antibody | E01/1H8
MBS226268-5x01mL	MyBiosource	5x0.1mL	EUR 2015

INI-1 antibody | E01/5G8
MBS226383-01mL	MyBiosource	0.1mL	EUR 485

INI-1 antibody | E01/5G8
MBS226383-5x01mL	MyBiosource	5x0.1mL	EUR 2015

PDK4 Antibody (E265)
MBS9204754-008mL	MyBiosource	0.08mL	EUR 210

PDK4 Antibody (E265)
MBS9204754-04mL	MyBiosource	0.4mL	EUR 430

PDK4 Antibody (E265)
MBS9204754-5x04mL	MyBiosource	5x0.4mL	EUR 1910

CTLA4 Antibody [1E6]
RF16011-002mg	ProSci	0.02 mg	EUR 229.7
Description: The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152, is a member of the immunoglobulin superfamily that is expressed by activated T cells and transmits an inhibitory signal to T cells (1,2). Both it and the homologous T-cell co-stimulatory protein CD28 bind to CD80 (B7-H1) and CD86 (B7-H2) on antigen-presenting cells (APCs) (3). Mutations in the CTLA-4 gene have been implicated in multiple autoimmune diseases (4). CTLA-4 also functions as an immune checkpoint protein, and anti- CTLA-4 antibodies have been successfully used in the treatment of cancer (5).

CTLA4 Antibody [1E6]
RF16011-01mg	ProSci	0.1 mg	EUR 594.26
Description: The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152, is a member of the immunoglobulin superfamily that is expressed by activated T cells and transmits an inhibitory signal to T cells (1,2). Both it and the homologous T-cell co-stimulatory protein CD28 bind to CD80 (B7-H1) and CD86 (B7-H2) on antigen-presenting cells (APCs) (3). Mutations in the CTLA-4 gene have been implicated in multiple autoimmune diseases (4). CTLA-4 also functions as an immune checkpoint protein, and anti- CTLA-4 antibodies have been successfully used in the treatment of cancer (5).

PDL2 Antibody [4E10]
RF16021-002mg	ProSci	0.02 mg	EUR 229.7
Description: PD-L2 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by co gnate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2, both of which are thought act as a negative regulator of T cell activation. However, it has been suggested that PD-L2 can act to stimulate an immunogenic response through and alternative receptor from PD-1.

PDL2 Antibody [4E10]
RF16021-01mg	ProSci	0.1 mg	EUR 594.26
Description: PD-L2 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by co gnate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2, both of which are thought act as a negative regulator of T cell activation. However, it has been suggested that PD-L2 can act to stimulate an immunogenic response through and alternative receptor from PD-1.

PDL1 Antibody [8E12]
RF16032-002mg	ProSci	0.02 mg	EUR 229.7
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4).

PDL1 Antibody [8E12]
RF16032-01mg	ProSci	0.1 mg	EUR 594.26
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4).